{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:48:58Z","timestamp":1772819338622,"version":"3.50.1"},"reference-count":131,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.clinthera.2013.09.008","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T14:30:26Z","timestamp":1382538626000},"page":"1669-1689","source":"Crossref","is-referenced-by-count":37,"title":["Medication Pain Management in the Elderly: Unique and Underutilized Analgesic Treatment Options"],"prefix":"10.1016","volume":"35","author":[{"given":"Timothy J.","family":"Atkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Fudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinetri","family":"Pandula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.09.008_bib1","unstructured":"US Dept of Health and Human Services, Administration of Aging. A profile of older Americans. http:\/\/www.aoa.gov\/Aging_Statistics\/Profile\/2011\/4.aspx. Accessed July 17, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib2","unstructured":"US Census. Table 102. Expectations of Life at Birth, 1970 to 2006, and Projections from 2010 to 2020. http:\/\/www.census.gov\/compendia\/statab\/2010\/tables\/10s0102.pdf. Accessed July 17, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1532-5415.2009.02376.x","article-title":"American Geriatric Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons","volume":"57","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"Part 1","key":"10.1016\/j.clinthera.2013.09.008_bib4","article-title":"The aging process. Geriatric Medicine Board review manual","volume":"Volume 1","author":"Dharmarajan","year":"2000","journal-title":"Geriatr Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.mpaic.2010.04.004","article-title":"Physiology of ageing","volume":"11","author":"Maguire","year":"2013","journal-title":"Anesth Intens Care Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/CIRCRESAHA.111.246876","article-title":"The intersection between aging and cardiovascular disease","volume":"110","author":"North","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2013.09.008_bib7","first-page":"245","article-title":"Brain white matter damage in aging and cognitive ability in youth and older age","volume":"13","author":"Hernandez","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.clinthera.2013.09.008_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cger.2013.05.006","article-title":"Anatomic and physiological changes of the aging kidney","volume":"3","author":"Karam","year":"2013","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1001\/jama.296.15.1858","article-title":"National surveillance of emergency department visits for outpatient adverse drug events","volume":"296","author":"Budnitz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.09.008_bib10","unstructured":"Institute of Medicine. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. http:\/\/www.iom.edu\/~\/media\/Files\/Report%20Files\/2011\/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research\/Pain%20Research%202011%20Report%20Brief.pdf. Accessed June 13, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/00003495-200060030-00004","article-title":"Oral versus topical NSAIDs in rheumatic diseases: a comparison","volume":"60","author":"Heyneman","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2013.09.008_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.09.008_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/11631550-000000000-00000","article-title":"Evolution of topical NSAIDS in the guidelines for treatment of osteoarthritis in elderly patients","volume":"29","author":"Arnstein","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2013.09.008_bib14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009","volume":"18","author":"Zhang","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2146\/ajhp110158","article-title":"Practical considerations for optimal transdermal drug delivery","volume":"69","author":"Durand","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2013.09.008_bib16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/106002808802201102","article-title":"Review of diclofenac and evaluation of its place in therapy as a nonsteroidal anti-inflammatory agent","volume":"22","author":"Skoutakis","year":"1988","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.clinthera.2013.09.008_bib17","unstructured":"King Pharmaceuticals. Flector (diclofenac epolamine) patch. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=f103f7e8-1253-43cb-9667-cd0d8f4d5500#nlm34084-4. Accessed June 3, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib18","first-page":"98","article-title":"Analgesic efficacy and safety of diclofenac epolamine topical patch (Flector patch) by location of injury in trials of acute pain: a pooled analysis of 5 trials.","volume":"10","author":"Lionberger","year":"2010","journal-title":"J Appl Res"},{"key":"10.1016\/j.clinthera.2013.09.008_bib19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/030079906X154123","article-title":"Short term treatment with diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: pooled analysis of two randomized clinical studies","volume":"22","author":"Bruhlman","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.09.008_bib20","first-page":"285","article-title":"Multicentre, double-blind controlled clinical study on the efficacy of diclofenac epolamine-Tissugel plaster in patients with epicondylitis","volume":"50","author":"Jenoure","year":"1997","journal-title":"Med Sport (Roma)"},{"key":"10.1016\/j.clinthera.2013.09.008_bib21","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1742-1241.2010.02474.x","article-title":"Topical diclofenac epolamine patch 1.3% for the treatment of acute pain caused by soft tissue injury","volume":"46","author":"McCarberg","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2013.09.008_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0044011-200929010-00001","article-title":"Diclofenac epolamine (Flector) patch: evidence for topical activity","volume":"29","author":"Petersen","year":"2009","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2013.09.008_bib23","unstructured":"US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Flector patch: clinical pharmacology and biopharmaceutics reviews. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021234s000_ClinPharmR.pdf. Accessed June 3, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib24","first-page":"81","article-title":"Diclofenac\/N-(2-hydroxyethyl) pyrrolidine: a new salt for an old drug","volume":"19","author":"Fini","year":"1993","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.clinthera.2013.09.008_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00044011-200727030-00002","article-title":"Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety","volume":"27","author":"Moore","year":"2007","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2013.09.008_bib26","unstructured":"US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Flector patch: medical review part 1. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021234s000_MedR_P1.pdf. Accessed June 3, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2125.2005.02484.x","article-title":"Favourable dermal penetration of diclofenac after administration to the skin using a novel sprays gel formulation","volume":"60","author":"Brunner","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2013.09.008_bib28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/rheumatology\/38.6.564","article-title":"Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy","volume":"38","author":"Rolf","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2013.09.008_bib29","first-page":"1138","article-title":"Comparison of tissue and plasma levels of ibuprofen after oral and topical administration","volume":"46","author":"Domenikus","year":"1996","journal-title":"Drug Res"},{"key":"10.1016\/j.clinthera.2013.09.008_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0009-9236(03)00165-6","article-title":"Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain","volume":"74","author":"Burian","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3810\/pgm.2011.07.2316","article-title":"Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies","volume":"123","author":"Brewer","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1526-4637.2010.00809.x","article-title":"Topical NSAID therapy for musculoskeletal pain","volume":"11","author":"Haroutiunian","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00520-006-0146-2","article-title":"Levorphanol: the forgotten opioid","volume":"15","author":"Prommer","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2013.09.008_bib34","first-page":"26","article-title":"Treatment of neuropathic pain: the role of unique opioid agents","volume":"11","author":"Zorn","year":"2011","journal-title":"Practical Pain Management"},{"key":"10.1016\/j.clinthera.2013.09.008_bib35","unstructured":"Levorphanol [package insert]. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed July 15, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib36","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa021420","article-title":"Oral opioid therapy for chronic peripheral and central neuropathic pain","volume":"348","author":"Rowbotham","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.36076\/ppj.2010\/13\/401","article-title":"Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective","volume":"13","author":"Manchikanti","year":"2010","journal-title":"Pain Physician"},{"key":"10.1016\/j.clinthera.2013.09.008_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2013.272","article-title":"Pharmaceutical overdose deaths, United States, 2010","volume":"309","author":"Jones","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.09.008_bib39","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMp1011512","article-title":"A flood of opioids, a rising tide of deaths","volume":"363","author":"Okie","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-3959(91)90002-F","article-title":"A call for more science, not more rhetoric, regarding opioids and neuropathic pain","volume":"47","author":"Dubner","year":"1991","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2013.09.008_bib41","first-page":"365","article-title":"Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain","volume":"35","author":"Arner","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2013.09.008_bib42","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0304-3959(98)00256-5","article-title":"Are opioids effective in relieving neuropathic pain?","volume":"80","author":"Dellemijn","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2013.09.008_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/J354v19n02_14","article-title":"Federation of State Medical Boards of the United States. Model policy for the use of controlled substances for the treatment of pain","volume":"19","year":"2005","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.clinthera.2013.09.008_bib44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jama.284.4.428","article-title":"for the Joint Commission on Accreditation of Healthcare Organizations. JCAHO pain management standards unveiled","volume":"284","author":"Philips","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2013.09.008_bib45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/00000542-199004000-00021","article-title":"Is the site of action of ketamine anesthesia the N-methyl-d-aspartate receptor?","volume":"72","author":"Yamamura","year":"1990","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clinthera.2013.09.008_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0885-3924(95)00010-V","article-title":"Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient","volume":"10","author":"Clark","year":"1995","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(00)01573-1","article-title":"d-morphine, but not l-morphine, has low micromolar affinity for the non-competitive N-methyl-d-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain","volume":"295","author":"Stringer","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2013.09.008_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.2003778","article-title":"An increase in synaptic NMDA receptors in the insular cortex contributes to neuropathic pain","volume":"6","author":"Qiu","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.clinthera.2013.09.008_bib49","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1523\/JNEUROSCI.5583-12.2013","article-title":"Hypofunction of glutamatergic transmission in the periaqueductal gray contributes to nerve-injury induced neuropathic pain","volume":"33","author":"Ho","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.clinthera.2013.09.008_bib50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0006-8993(94)91538-5","article-title":"Inhibition of opiate tolerance by non-competitive N-methyl-d-aspartate receptor antagonists","volume":"633","author":"Trujillo","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.clinthera.2013.09.008_bib51","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.pain.2005.03.004","article-title":"MorphiDex (morphine sulfate\/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multi-center, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance","volume":"115","author":"Galer","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2013.09.008_bib52","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib53","first-page":"46","article-title":"for the CE Program of the University of Connecticut School of Pharmacy and Drug Topics. Opioid pain management: balancing risks and benefits","author":"Fudin","year":"2011","journal-title":"Drug Topics"},{"key":"10.1016\/j.clinthera.2013.09.008_bib54","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1124\/jpet.103.055814","article-title":"Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, densensitization, internalization, and down regulation","volume":"307","author":"Wang","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib55","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0028-3908(92)90121-5","article-title":"Kappa 3 receptors and levorphanol-induced analgesia","volume":"31","author":"Tive","year":"1992","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2013.09.008_bib56","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1046\/j.1471-4159.1997.68051846.x","article-title":"Differential agonist regulation of the human K-opioid receptor","volume":"68","author":"Blake","year":"1997","journal-title":"Neurochemistry"},{"key":"10.1016\/j.clinthera.2013.09.008_bib57","first-page":"3","article-title":"Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain","volume":"41","author":"Dixon","year":"1983","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.clinthera.2013.09.008_bib58","unstructured":"Practical pain management: opioid calculator. http:\/\/opioidcalculator.practicalpainmanagement.com. Accessed August 15, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib59","unstructured":"Opioid chemistry. http:\/\/paindr.com\/wp-content\/uploads\/2012\/05\/Opioid-Chemistry-09-2011.pdf. Accessed August 15, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib60","first-page":"46","article-title":"A mathematical model for methadone conversion examined","author":"Fudin","year":"2012","journal-title":"Practical Pain Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib61","unstructured":"Centers for Disease Control and Prevention. CDC features: prescription painkiller overdoses: methadone. http:\/\/www.cdc.gov\/features\/vitalsigns\/methadoneoverdoses\/. Accessed July 4, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib62","unstructured":"Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief\u2014United States, 1999\u20132010. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6126a5.htm?s_cid=mm6126a5_w. Accessed July 4, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/15360288.2013.803512","article-title":"Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone","volume":"27","author":"Fudin","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.clinthera.2013.09.008_bib64","unstructured":"Butrans [package insert]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021306s016lbl.pdf. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib65","unstructured":"Buprenex [package insert]. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib66","unstructured":"Subutex [package insert]. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib67","unstructured":"Suboxone [package insert]. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed August 2, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bja\/aeg133","article-title":"Old dog\u2013new (ma)trix","volume":"90","author":"Budd","year":"2003","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2013.09.008_bib69","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain: safety aspects","volume":"2","author":"Likar","year":"2006","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib70","series-title":"Opium: A History","author":"Booth","year":"1996"},{"key":"10.1016\/j.clinthera.2013.09.008_bib71","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/clpt.1980.219","article-title":"Buprenorphine kinetics","volume":"28","author":"Bullingham","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib72","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"A comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2013.09.008_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bja\/57.2.192","article-title":"Clinical actions of fentanyl and buprenorphine: the significance of receptor binding","volume":"57","author":"Boas","year":"1985","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2013.09.008_bib74","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/00000542-200606000-00019","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers","volume":"104","author":"Yassen","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clinthera.2013.09.008_bib75","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacologic profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"key":"10.1016\/j.clinthera.2013.09.008_bib76","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200363190-00003","article-title":"Transdermal buprenorphine","volume":"63","author":"Evans","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2013.09.008_bib77","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpainsymman.2012.06.014","article-title":"Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels","volume":"46","author":"Kapil","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib78","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1476-5381.1980.tb07041.x","article-title":"A classification of opiate receptors that mediate antinociception in animals","volume":"68","author":"Tyers","year":"1980","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2013.09.008_bib79","unstructured":"Buprenorphine transdermal patch: clinical expert report. Aachen, Germany: Gr\u00fcnenthal GmbH; 2000"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.09.008_bib80","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s100670200031","article-title":"Buprenorphine in a transdermal therapeutic system\u2014a new option","volume":"21","author":"Bohme","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2013.09.008_bib81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2013.09.008_bib82","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u00b5-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2013.09.008_bib83","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jpainsymman.2011.04.006","article-title":"Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-na\u00efve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study","volume":"42","author":"Steiner","year":"2011","journal-title":"Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib84","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jpain.2011.06.003","article-title":"Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study","volume":"12","author":"Steiner","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2013.09.008_bib85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jpainsymman.2010.01.013","article-title":"A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans Seven-Day Patches) with buprenorphine sublingual tablets (Temgesic\u00ae) in patients with osteoarthritis pain","volume":"40","author":"James","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib86","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF03262278","article-title":"Treatment of chronic pain in older people: evidenced-based choice of strong-acting opioids","volume":"29","author":"Ojik","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2013.09.008_bib87","first-page":"87","article-title":"Buprenorphine and sustained release morphine\u2014effect and side-effects in chronic use","volume":"4","author":"Bach","year":"1991","journal-title":"Pain Clinic"},{"key":"10.1016\/j.clinthera.2013.09.008_bib88","first-page":"19","article-title":"use in daily practice, benefits for patients","volume":"133","author":"Radbruch","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.clinthera.2013.09.008_bib89","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.clinthera.2013.09.008_bib90","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1185\/030079905X53315","article-title":"Transdermal buprenorphine in clinical practice\u2014a post-marketing surveillance study in 13179 patients","volume":"21","author":"Griessinger","year":"2005","journal-title":"Curr Med Res"},{"key":"10.1016\/j.clinthera.2013.09.008_bib91","unstructured":"Purdue Pharma. Initiation and titration guide. https:\/\/www.butrans.com\/images\/pdf\/InitationandTitration.pdf. Accessed July 27, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib92","unstructured":"National Cancer Institute Pain (PDQ). Pharmacologic management. http:\/\/www.cancer.gov\/cancertopics\/pdq\/supportivecare\/pain\/HealthProfessional\/Table3. Accessed July 28, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib93","unstructured":"American Academy of Hospice and Palliative Medicine. Guidelines for prescribing opiates for hospice and palliative care patients. http:\/\/www.aahpm.org\/pdf\/equianalgesictable.pdf. Accessed August 10, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib94","article-title":"Equianalgesic Dosing of Opioids for Pain Management","author":"PL","year":"2012","journal-title":"Pharmacist\u2019s Letter\/Prescriber\u2019s Letter"},{"key":"10.1016\/j.clinthera.2013.09.008_bib95","doi-asserted-by":"crossref","first-page":"ES59","DOI":"10.36076\/ppj.2012\/15\/ES59","article-title":"Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine","volume":"15","author":"Daitch","year":"2012","journal-title":"Pain Physician"},{"key":"10.1016\/j.clinthera.2013.09.008_bib96","series-title":"Demystifying Opioid Conversion Calculations","author":"McPherson","year":"2010"},{"key":"10.1016\/j.clinthera.2013.09.008_bib97","author":"Perkins"},{"key":"10.1016\/j.clinthera.2013.09.008_bib98","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0885-3924(01)00294-9","article-title":"Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing","volume":"22","author":"Pereira","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib99","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jpainsymman.2007.01.006","article-title":"Switching from transdermal drugs: an observational \u201cn of 1\u201d study of fentanyl and buprenorphine","volume":"34","author":"Mercandente","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2005.02.012","article-title":"Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non-cancer pain: results of a prospective cohort study","volume":"27","author":"Sittl","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib101","first-page":"61","article-title":"Evaluation and comparison of online equianalgesic opioid dose conversion calculators","volume":"13","author":"Shaw","year":"2013","journal-title":"Practical Pain Manage"},{"key":"10.1016\/j.clinthera.2013.09.008_bib102","unstructured":"Nucynta (tapentadol HCl) [package insert]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022304s007s008s009s011s012lbl.pdf. Accessed August 14, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib103","unstructured":"Nucynta E.R. (tapentadol HCl) [package insert]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/200533s001lbl.pdf. Accessed August 14, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib104","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5414\/CP201722","article-title":"Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations","volume":"51","author":"Gohler","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib105","first-page":"454","article-title":"Antidepressants in pain management","volume":"3","author":"Carter","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.clinthera.2013.09.008_bib106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.107.126052","article-title":"(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties","volume":"323","author":"Tzschentke","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib107","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJM199205073261904","article-title":"Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy","volume":"326","author":"Max","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib108","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hup.621","article-title":"Clinical experience with dual action antidepressants in different chronic pain syndromes","volume":"19","author":"Briley","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinthera.2013.09.008_bib109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","article-title":"American Geriatric Society. American Geriatric Society updated Beers criteria for potentially inappropriate medication use in older adults","volume":"60","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2013.09.008_bib110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjopharm.2007.03.003","article-title":"Retrospective evaluation of medication appropriateness and clinical pharmacist drug therapy recommendations for home-based primary care veterans","volume":"5","author":"Davis","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinthera.2013.09.008_bib111","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0028-3908(79)90028-5","article-title":"Enhancement of morphine analgesia by tricyclic antidepressants","volume":"18","author":"Malseed","year":"1979","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2013.09.008_bib112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410130209","article-title":"Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system","volume":"13","author":"Botney","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2013.09.008_bib113","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)11227-5","article-title":"Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an \u2018atypical\u2019 opioid analgesic","volume":"260","author":"Raffa","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib114","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3565(25)39454-1","article-title":"Complementary and synergistic antinociceptive interaction between enantiomers of tramadol","volume":"267","author":"Raffa","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib115","first-page":"1029","article-title":"Influence of tramadol on neurotransmitter systems of the rat brain","volume":"46","author":"Frink","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2013.09.008_bib116","unstructured":"Ultram (tramadol HCl) [package insert]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020281s032s033lbl.pdf. Accessed August 15, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib117","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0009-9236(96)90211-8","article-title":"The hypoalgesic effect of tramadol in relation to CYP2D6","volume":"60","author":"Poulsen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib118","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome [published correction appears in: N Engl J Med. 2007;356:2437]","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib119","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clinthera.2009.02.009","volume":"31","author":"Hartrick","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.09.008_bib120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1185\/03007990902728183","article-title":"A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain","volume":"25","author":"Daniels","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.09.008_bib121","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1185\/03007990902816970","article-title":"Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study","volume":"25","author":"Hale","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.09.008_bib122","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2013.09.008_bib123","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2013.09.008_bib124","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1185\/03007995.2010.537589","article-title":"Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial","volume":"27","author":"Schwartz","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2013.09.008_bib125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1533-2500.2010.00397.x","article-title":"Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain","volume":"10","author":"Wild","year":"2010","journal-title":"Pain Pract"},{"key":"10.1016\/j.clinthera.2013.09.008_bib126","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03190478","article-title":"Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects","volume":"32","author":"Terlinden","year":"2007","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2013.09.008_bib127","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2165\/11535390-000000000-00000","article-title":"Population pharmacokinetics of tapentadol immediate-release (IR) in healthy subjects and patients with moderate to severe pain","volume":"49","author":"Xu","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2013.09.008_bib128","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/j.1875-9114.2012.01101.x","article-title":"Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery","volume":"32","author":"Pizzi","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2013.09.008_bib129","unstructured":"Dolophine [package insert]. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=7a4840d6-98e3-4523-81a0-ef0b3a47d0c2. Accessed August 14, 2013."},{"key":"10.1016\/j.clinthera.2013.09.008_bib130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","article-title":"Clinical guidelines: QTc interval screening in methadone treatment","volume":"150","author":"Krantz","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2013.09.008_bib131","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1155\/2011\/323985","article-title":"Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients","volume":"16","author":"Vorsanger","year":"2011","journal-title":"Pain Res Manag"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813009594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813009594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T18:06:33Z","timestamp":1746036393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813009594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":131,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0149291813009594"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.09.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}